# Impilo Orphan Drugs AB — Form D

Impilo Orphan Drugs AB of STOCKHOLM, V7, a pooled investment fund, filed a Form D exempt-offering notice with the SEC on 2024-09-30. $80.5M was reported sold. Industry: Pooled Investment Fund.

## Offering

- Filed: 2024-09-30
- Form: D
- Accession: 0001315863-24-000688
- Industry: Pooled Investment Fund
- Exemptions: 06b, 3C, 3C.7
- Amount sold: $80.5M
- Investors: 12
- Date of first sale: 2024-09-19
- Security types: equity, fund interests
- Revenue range: Decline to Disclose
- SEC file number: 021-525326

## Issuer

- Name: Impilo Orphan Drugs AB
- CIK: 0002037323
- Entity type: Other
- Jurisdiction: SWEDEN
- Incorporated: 2024
- Address: REGERINGSGATAN 48, STOCKHOLM, V7, SE-111 56
- Phone: 46 70943 23 30

## Officers, directors & promoters (4)

| Name | Role | Location |
| --- | --- | --- |
| Tor Ulf Edvard Hubendick | Director | Stockholm, V7 |
| Karl Gustav Johan Fredrik Jungdalen Lundgren | Director | Stockholm, V7 |
| Johan Fredrik Odin | Director | Stockholm, V7 |
| N/A Impilo Holding AB | Promoter | Stockholm, V7 |

## More

- [CIK 2037323 on SEC EDGAR (source of record)](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=2037323&type=&dateb=&owner=include&count=40)
- [This page as markdown (for LLM agents)](https://search.stillhousedata.com/formd/0001315863-24-000688.md)
- [Search all SEC filings, advisers and people on Adviser Search](https://search.stillhousedata.com/)

---

Source: public SEC filing data via Adviser Search (https://search.stillhousedata.com).
Agents: this data is also queryable via MCP tools and read-only SQL — see https://search.stillhousedata.com/llms.txt.